

## TITLE PAGE

### Article title

Diagnostic accuracy of cerebrospinal fluid and blood biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis

### Author information

Nicole Rübsamen, Ph.D.<sup>1\*</sup>, Stephanie Pape, MPH, MSc<sup>1\*</sup>, Stefan Konigorski, Dr. rer. nat.<sup>2,3</sup>,  
Antonia Zapf, Dr. rer. nat.<sup>4</sup>, Gerta Rücker, Dr. rer. nat.<sup>5</sup>, André Karch, MD<sup>1</sup>

1. Institute of Epidemiology and Social Medicine, University of Münster, Germany.
2. Molecular Epidemiology Research Group, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
3. Digital Health and Machine Learning Research Group, Hasso Plattner Institute for Digital Engineering, Potsdam, Germany.
4. Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
5. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.

\* These authors contributed equally to the manuscript.

### Complete contact information for corresponding author

Nicole Rübsamen, Ph.D.

Institute of Epidemiology and Social Medicine

University of Münster

Domagkstraße 3

48149 Münster

Germany

Phone: +49 251 83 55520

Fax: +49 251 83 55300

[ruebsame@uni-muenster.de](mailto:ruebsame@uni-muenster.de)

ORCID: 0000-0003-2198-5577

## **ABSTRACT**

### **Objective**

To conduct a systematic review of cerebrospinal fluid (CSF) and blood biomarkers as diagnostic tests for sporadic Creutzfeldt-Jakob disease (sCJD) in a specialised care setting and to compare diagnostic accuracies in a network meta-analysis (NMA).

### **Methods**

We searched Medline, Embase, and the Cochrane Library for diagnostic studies of sCJD biomarkers. Risk of bias was assessed with the QUADAS-2 tool. We used a generalised bivariate model to conduct individual biomarker meta-analyses, and to estimate between-study variability. To investigate sources of heterogeneity, we performed subgroup analyses based on QUADAS-2 quality and clinical criteria. For the NMA, we applied a Bayesian beta-binomial ANOVA model. The study protocol was registered at PROSPERO (CRD42019118830).

### **Results**

Out of 2,976 publications screened, we included 16 studies, which investigated 14-3-3 $\beta$  Western blot (n=13), 14-3-3 $\gamma$  ELISA (n=3), NfL (n=1), NSE (n=1), p-tau181/t-tau ratio (n=2), RT-QuIC (n=6), S100B (n=3), t-tau (n=12), and t-tau/A $\beta$ 42 ratio (n=1) in CSF. No included study investigated blood biomarkers. Many diagnostic studies excluded had strong limitations in study design. In the NMA, RT-QuIC (0.93; 95% CI [0.87, 0.96]) and NfL (0.94 [0.81, 0.99]) were the most sensitive biomarkers. RT-QuIC was the most specific biomarker (0.96 [0.86, 0.99]), and had the highest balanced accuracy (0.94). Heterogeneity in accuracy estimates was high between studies, especially for specificity.

### **Conclusions**

Our NMA identified RT-QuIC as the overall most accurate biomarker, partially confirming current guidelines. The severe shortcomings identified in many diagnostic studies for sCJD biomarkers need to be addressed in future studies in the field.

## TEXT

### Introduction

The sporadic form of Creutzfeldt-Jakob disease (sCJD) is the world's most common human prion disease with an incidence of about 1–2 cases per million and year.<sup>1,2</sup> The reference standard for the definite diagnosis of sCJD is the post-mortem neuropathological examination of the brain, which is of little benefit to patients during their lifetime. An alternative is the use of a diagnostic composite reference standard.<sup>3,4</sup> Based on clinical criteria combined with either defined changes in magnetic resonance imaging (MRI), a characteristic electroencephalogram (EEG), or a positive biomarker test, patients are differentiated into non-sCJD patients as well as probable and possible sCJD cases.

Detection of the proteins 14-3-3 and the PrPSc aggregation assay RT-QuIC (Real-Time Quaking Induced Conversion) are currently incorporated in the diagnostic composite reference standard.<sup>3,5</sup> Other biomarkers, e.g. tau (total tau [t-tau] or phosphorylated tau [p-tau]), neuron-specific enolase (NSE), neurofilament light chain (NfL), and S100B, have been proposed as an addition or replacement option for the biomarkers in the composite criteria for the differential diagnosis of sCJD. There is no evidence from systematic reviews and diagnostic meta-analyses that have performed a comparative investigation of the accuracy of biomarkers suitable for the differential diagnosis of sCJD. Previous reviews in the field focused either on a single biomarker<sup>6</sup>, or did not formally compare biomarkers in a meta-analysis.<sup>7</sup> We, therefore, conducted a network meta-analysis based on a systematic review to compare the accuracy of established biomarker tests measured in the blood or cerebrospinal fluid (CSF) to diagnose sCJD in a specialised care setting under real-life conditions.

## Methods

### Search strategy and selection criteria

For this systematic review and meta-analysis, we systematically searched Medline, Embase, and the Cochrane Library for diagnostic studies that assessed the accuracy of blood or CSF biomarkers to diagnose sCJD (Table e-1). One author (SP) searched all databases on 25<sup>th</sup> July 2018 (initial search) and 23<sup>rd</sup> September 2020 (update). The search term for Medline was (((((Biomarker) OR biomarkers [MeSH Terms])) OR ((Diagnosis) OR diagnosis [MeSH Terms]))) AND (((Creutzfeldt Jakob disease) OR CJD)) OR cjd creutzfeldt jakob disease [MeSH Terms]) AND ((CSF OR cerebrospinal) OR (blood or serum or plasma)). SP merged all search results and removed duplicates.

Studies were included if they assessed blood or CSF biomarkers' accuracy for the differentiation of sCJD from other diseases in a specialised care setting (Table e-2). Eligible studies had to use established diagnostic criteria of sCJD<sup>3,4</sup> and established diagnostic criteria for diseases in the non-CJD groups (e.g., Alzheimer's disease, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, alcohol-induced dementia) as reference standard. The non-CJD group had to represent patients suspected as a CJD case and referred to the specialised care centre for a first diagnostic workup. The biomarker tests had to be performed during the patient's first diagnostic workup for her/his symptoms without a pre-defined diagnosis. Furthermore, the studies had to provide sufficient information to construct a diagnostic contingency table (i.e., true and false positives and negatives). There were no constraints regarding time, language, stage of sCJD, patient population, type of biomarker, reference standard, or study design. Different restrictions were used for specific biomarkers: Results for 14-3-3 and RT-QuIC were included if there was no risk of incorporation bias,<sup>8</sup> i.e. if 14-3-3 or RT-QuIC were not incorporated in the reference standard used. Results for t-tau were included if the cut-off used to classify a test result

as positive/negative was within  $\pm 10\%$  of the recommended cut-off 1300 pg/mL.<sup>9</sup> For all other biomarkers, the cut-off values used in the study needed to be based on external knowledge or training datasets. Methods used for measurement of S100B differed between studies. We allowed, therefore, for different cut-off values as long as they fulfilled the criteria above. However, we excluded measurements of RT-QuIC using the first-generation assay (PQ-CSF) because this technology is no longer used in clinical practice. Only measurements of RT-QuIC using the second-generation assay (IQ-CSF) were included.

Two authors (SP and AK) independently reviewed all titles, abstracts, and, if publications were included based on this information, full texts. Discrepancies were resolved in a consensus meeting. An agreement was reached regarding all discrepancies so that referral to a third reviewer was not necessary.

All reference lists of publications included in the final systematic review were searched for additional studies that were missed, and these studies were further included in the review. Moreover, we discussed with experts from sCJD-specialised care centres if the search strategy missed studies known to them. We did not specifically assess grey literature sources in addition to this strategy because due to the rarity of sCJD and the clustering of patients in few specialised care settings worldwide, newly obtained findings are generally made available in manuscript form.

The study protocol and statistical analysis plan were registered with PROSPERO on January 9<sup>th</sup>, 2019 (CRD42019118830) after the beginning of preliminary searches, piloting of the study selection process, and formal screening of search results against eligibility criteria; however, before data extraction, risk of bias (quality) assessment and data analysis had been started.

## Data extraction and quality assessment

SP extracted clinical and demographic information (number of patients, clinical diagnosis, age, sex, setting, recruitment, and sampling procedure) as well as details of the assays and cut-offs used. Two authors (NR and SP) independently extracted the number of true and false positives and negatives (stratified by the level of certainty of sCJD diagnosis). An agreement was reached regarding all discrepancies. We contacted the corresponding authors if further information was needed.

SP, AK, and NR performed their risk of bias assessments for the included studies independently using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool, the only validated tool for estimating risk of bias in diagnostic studies.<sup>10</sup> QUADAS-2 covers quality evaluations in four different domains (patient selection, index test, reference standard, flow and timing) by using signalling questions related to the research question, and is supplemented by applicability inquiries. AK and SP first piloted the tool by using two randomly selected publications.<sup>9,11</sup> Satisfactory agreement was reached in all domains so that the QUADAS-2 signalling questions were retained unchanged for the assessment of the included studies (Table e-3).

## Data analysis

All analyses were performed with R version 4.0.3.<sup>12</sup>

### *Systematic review*

We calculated Krippendorff's alpha<sup>13</sup> to assess the reliability of the risk of bias assessment between the investigators.

### *Meta-analyses of individual biomarkers*

We tabulated true positives, false negatives, false positives, and true negatives in patients with and without sCJD, stratified by study and level of certainty of sCJD diagnosis. Based on this, we calculated estimates of sensitivity and specificity and their 95% confidence intervals (CI). To investigate publication bias, we constructed funnel plots of effective sample size versus the estimated log diagnostic odds ratios and did a regression test of asymmetry.<sup>14</sup> To synthesise data, we implemented the generalised linear mixed model approach by Chu and Cole,<sup>15</sup> which uses a bivariate binomial model to jointly analyse pairs of sensitivity and specificity, using the *glmer* function in the R package *lme4* (version 1.1-25).<sup>16</sup> This approach allows estimating the correlation between true positive rate (TPR) and false-positive rate (FPR) as well as the between-study standard deviation (SD) for both of them via random effects, which provides information on the heterogeneity of the results.<sup>17</sup> To investigate sources of heterogeneity, we performed subgroup analyses based on QUADAS-2 quality and clinical criteria. Although there exist approaches for meta-analyses of diagnostic test accuracy studies with multiple cut-offs, we decided against using them because biomarker cut-offs were either homogeneous or were applied to different technical platforms, so that different measurement scales were used.

We repeated all analyses for different levels of certainty of sCJD diagnosis: 1) definite sCJD cases, 2) definite and probable sCJD cases, and 3) definite, probable, and possible sCJD cases.

### *Network meta-analysis*

To compare the diagnostic accuracy of different biomarkers, we applied a diagnostic network meta-analysis (NMA) approach for evidence synthesis. We used the beta-binomial analysis of variance model for NMA of diagnostic test accuracy data as described by Nyaga et al.<sup>18</sup> to combine direct and indirect evidence simultaneously. This arm-based generalised linear mixed

model models sensitivity and specificity as repeated measures jointly through a copula function and assumes that the missing tests/arms are missing at random. The models were fitted in the Bayesian framework with  $\text{beta}(1,1) = U(0,1)$  as prior distribution on the hyper-parameters using Stan<sup>19</sup> through the R package *rstan* (version 2.21.2).<sup>20</sup> We repeated the network meta-analyses for different levels of certainty of sCJD diagnosis (as described above).

## Data Availability Statement

All data generated or analysed during this study are included in this article.

## Results

### Systematic review

Our database search retrieved 2,976 articles. After reviewing the titles and abstracts, we excluded 2,668 articles, mostly because these studies were not diagnostic studies, they duplicated data already included, or the case definition or study population was not appropriate. After a full-text review of the remaining 308 articles, we found that 86 studies were not diagnostic studies and that 32 articles reported duplicated data. Among the remaining 190 diagnostic studies, we excluded 171 studies because of inappropriate study populations or missing information on key study characteristics, leaving 19 articles for risk of bias assessment (Figure 1).

Sufficient inter-rater reliability was achieved in the core areas of patient selection, blinding and missing values, which are particularly important for quality assessment (Table e-4). The reviewers discussed all 19 studies together, and differences in the risk of bias assessment (which were mainly based on high vs unclear risk of bias in studies where specific features were only partially reported) could be fully resolved (Table e-4). Based on high or unclear risks of bias and

poor applicability, the studies by Hamlin et al.,<sup>11</sup> Rudge et al.,<sup>21</sup> and Wang et al.<sup>22</sup> were excluded, leaving 16 studies for further quantitative analyses<sup>9,23–37</sup> (Table 1).

Fourteen of these studies investigated 14-3-3 $\beta$  via Western blot. The results regarding 14-3-3 $\beta$  in the study by Sanchez-Juan et al.<sup>34</sup> were, however, excluded due to high risk of incorporation bias, leaving 13 studies that investigated 14-3-3 $\beta$ . Three studies investigated 14-3-3 $\gamma$  via ELISA. NfL, NSE, p-tau181/t-tau ratio, RT-QuIC, S100B, and t-tau/A $\beta$ 42 ratio were investigated in one, one, two, six, three, and one studies, respectively (Table 1). Thirteen studies investigated t-tau, but the study by Leitão et al.<sup>32</sup> used the cut-off 1035 pg/mL to classify a test result as positive, which was outside our pre-defined interval around the recommended cut-off of 1300 pg/mL.<sup>9</sup> The results regarding tau in the study by Leitão et al.<sup>32</sup> were, thus, excluded. Studies included in these analyses investigated between one and five biomarkers in the same study population, providing direct comparisons for some of the biomarkers involved.

#### Meta-analyses of individual biomarkers

The regression tests of asymmetry in the funnel plots did not indicate publication bias for any studied biomarkers (Figure e-1). Among definite sCJD cases, the range of observed sensitivities was 0.80 to 0.99 for 14-3-3 $\beta$ , 0.88 to 0.96 for 14-3-3 $\gamma$ , 0.86 to 0.96 for RT-QuIC, 0.65 to 0.93 for S100B, and 0.77 to 0.94 for t-tau (Figure 2). The range of observed specificities was 0.24 to 0.97 for 14-3-3 $\beta$ , 0.69 to 0.95 for 14-3-3 $\gamma$ , 0.95 to 0.99 for RT-QuIC, 0.90 to 0.93 for S100B, and 0.33 to 0.95 for t-tau (Figure 2). Individual meta-analyses of NfL, NSE, p-tau181/t-tau ratio, and t-tau/A $\beta$ 42 ratio were not conducted due to the low number of studies. Heterogeneity, estimated via SD (TPR) and SD (FPR), was high for all individual meta-analyses so that no pooled estimates were reported (Table e-5–Table e-9, Figure e-4–Figure e-8). Ranges of observed sensitivities and specificities were similar when including lower levels of certainty of sCJD

diagnosis (Figure e-2, Figure e-3) except for the specificity of S100B, which was considerably lower when all levels of certainty were included. When including definite sCJD cases only, heterogeneity among studies was highest for the sensitivity of S100B (SD (TPR): 0.91); heterogeneity in specificity was high for all biomarkers but S100B (Figure 2).

There were various sources of heterogeneity for all biomarkers in all scenarios; the most important ones (identified by a decrease of heterogeneity in the respective subgroup analysis) were the definition of the study population (especially concerning the group without CJD), study design, blinding of the reference standard and clinical characteristics of the patients (Table e-5–Table e-9, Figure e-4–Figure e-8).

#### Network meta-analysis

Since differences in estimates between studies in the individual meta-analyses were consistent across different biomarkers, an evidence-synthesis approach based on the combination of intra-study differences was used to derive pooled estimates of diagnostic accuracy. Figure 3 summarises the direct evidence from all studies. In the NMA analysis based on definite sCJD cases only, RT-QuIC was the most specific (0.96 [0.85, 1.00]) and the second most sensitive (0.91 [0.83, 0.96]) biomarker (Figure 4, Table 2). The balanced accuracy ( $(\text{sensitivity} + \text{specificity})/2$ ) was also highest for RT-QuIC (0.93). While NfL had the highest sensitivity in this NMA analysis (0.92 (0.72, 0.99)), its specificity was the lowest among all biomarkers (0.45 (0.15, 0.79)). Ratios involving t-tau (p-tau181/t-tau, t-tau/A $\beta$ 42) had higher accuracies than t-tau alone (Table 2); however, sensitivities and specificities were estimated with wider 95% CI (Figure 4) because fewer studies investigated these ratios than t-tau alone.

The pooled sensitivities and specificities of most included biomarkers did not change much ( $\pm 0.01$ ) when including lower levels of certainty of sCJD diagnosis (Figure 4). As an exception,

specificity increased from 0.75 to 0.80 for 14-3-3 $\gamma$  and from 0.75 to 0.77 for t-tau, while it decreased from 0.84 to 0.81 for S100B. At the same time, the sensitivity increased from 0.74 to 0.77 for S100B. RT-QuIC was the most accurate test in among all levels of certainty of sCJD diagnosis.

## **Discussion**

In our systematic review, we evaluated for the first time systematically the diagnostic accuracy of proposed CSF and blood biomarkers for the differential diagnosis of sCJD in a specialised care setting. We applied the innovative concept of a diagnostic network meta-analysis to compare accuracies between different biomarkers. We found that RT-QuIC had the best-balanced accuracy and specificity throughout all scenarios.

Most of the 190 diagnostic accuracy studies retrieved in this systematic review did not meet the highest quality requirements of evidence-based medicine. All diagnostic studies evaluated were subject to methodological limitations, partly due to the rare disease situation, the lack of a uniform reference standard, and various forms of bias. Even the 16 (8.4%) studies included in the final analysis had limitations mainly based on the study population's composition and the timing of the definition of the reference standard.

Subgroup analysis results indicate that the heterogeneity observed was mainly caused by choice of study population and less by methodological quality or clinical criteria. Specificity estimates showed the highest heterogeneity since most biomarkers used in the sCJD context are unspecific markers of neurodegeneration so that the composition of the non-sCJD group is crucial. One exception was RT-QuIC, which is the only available prion-specific biomarker so far. Although we only included diagnostic studies that reflected the real-world referral setting of a specialised

care centre, the proportion of other neurodegenerative diseases in the non-CJD group might have been heterogeneous based on country-specific referral patterns or local research foci.

Many methodological constraints found in our systematic review were typical for diagnostic accuracy studies dealing with low-prevalence settings. Here, the gold standard phase III diagnostic study design with the recruitment of consecutive patients suspected of the target condition who subsequently receive the index test and the reference standard is rarely applied in practice because of the large overall sample size, the long study duration and the high costs. To ensure optimal diagnostic accuracy estimates under these preconditions, Holtman and colleagues provide a general guide for six applicable designs in different low-prevalence situations.<sup>38</sup> The design's selection best suitable should be made based on the specific constraints of the particular situation (e.g. patient selection, the invasiveness of an index test or reference standard, the target condition itself). The designs suggested by Holtman and colleagues offer reasonable approaches to improve the methodological quality and evidence for diagnostic studies in sCJD. Moreover, taking into account the recommendations of the regulatory authorities EMA<sup>39</sup> and FDA<sup>40</sup>, the Cochrane Collaboration<sup>41</sup>, the QUADAS-2 tool<sup>10</sup>, and the STARD checklist<sup>42</sup> can considerably contribute to ensuring high-quality diagnostic accuracy studies.

The inclusion/exclusion criteria and signalling questions of the QUADAS-2 tool that we applied do not only represent the prerequisites for conducting valid meta-analyses, but also reflect the patient characteristics and basic medical criteria that are essential for reliable decision-making in a real-world clinical setting. In the absence of this information in diagnostic accuracy studies, such studies provide only limited evidence to support the medical diagnosis of sCJD in everyday clinical practice. If relevant patient data are not reported and cannot be retrieved, diagnostic studies may be of little use for the reader because the applicability and generalisability of the results remain unclear.

By excluding healthy individuals and focusing on patients representing true differential diagnoses such as Alzheimer's disease or other rapid progressive dementia, studies increase their relevance for clinical decision-making. It has to be assessed carefully if certain diagnoses, which are more prevalent than sCJD and can be diagnosed easily using a set of diagnostic criteria for this disease, can be removed from the field of clinically relevant differential diagnoses of sCJD if sCJD diagnosis is already ruled out based on these alternative criteria<sup>43</sup>. In such a case, it may also be reasonable to consider these diagnostic tests directly in the evaluation of potential sCJD patients. Our NMA results imply that RT-QuIC is overall the most accurate biomarker with both high sensitivity and specificity. RT-QuIC has already been proposed as an addition to 14-3-3 positivity for the composite reference standard,<sup>44</sup> and an updated reference standard has been validated by the authors of the German CJD guideline.<sup>45</sup> However, it is currently unclear how to best combine RT-QuIC and 14-3-3 in the setting of the complex composite reference standard. A naïve approach would be to use the easily applicable, but still highly sensitive 14-3-3 as screening test or initial index test in patients with suspected sCJD. Only patients tested positively could then be further examined according to the composite reference standard, including RT-QuIC instead of 14-3-3 to confirm sCJD diagnosis. Abu-Rumeileh et al.<sup>23</sup> explored the combinations of two biomarkers (a surrogate marker plus RT-QuIC). Integrating their data in our NMA found that NfL had the highest sensitivity for all certainty levels of sCJD diagnosis, but the lowest specificity, resulting in the poorest balanced accuracy. From our perspective, the issues of biomarker test combinations and screening tests need further validation. High-quality primary studies with paired information on at least two biomarkers for each individual are necessary to develop more sophisticated strategies to combine biomarkers. Moreover, estimates for the expected benefit for the patient are needed to make inferences about the likely impact on patient-important outcomes.<sup>46</sup>

## Strengths and limitations

Our systematic review provides the most extensive evaluation of biomarkers for the differential diagnosis of sCJD. It is the first one offering head-to-head comparisons. Despite considerable heterogeneity between studies, this comparison was possible since we applied a specific form of diagnostic network meta-analysis. We only included studies that mimicked a phase III diagnostic study design, and were performed in the real-life target population. By doing so, we wanted to provide the best available evidence to support clinicians in daily real-world clinical decision-making in the differential diagnosis of sCJD. All the included studies had a moderate risk of bias in at least one of the categories assessed so that residual bias in estimates cannot be ruled out. Our systematic review included CSF and blood biomarkers, but could not identify a study based on serum or plasma biomarkers, which met our inclusion criteria. Compared to CSF biomarkers, serum biomarkers have many advantages e.g. with respect to invasiveness, patient acceptability, cost and time-effectiveness, and population-level feasibility, making them beneficial complementary partners of CSF biomarkers or neuroimaging.<sup>47</sup> However, no study using serum biomarkers could be included in our systematic review. Both, comparing bio-fluid biomarkers to and combining them with neuroimaging is a relevant research field, as the recent study of Bizzi et al.<sup>25</sup> showed. We included the biomarker data from this study in our NMA, but decided against an extension of our work to imaging markers, as this would result in more complex requirements about what needs to be reported in the respective studies and about how the studies were performed. This was beyond the scope of this work, but provides an interesting avenue for future studies. Due to the rare disease situation and patients' treatment in a few specialised centres worldwide, the same patients might have been included in more than one study within the review. Although no author has explicitly described this, frozen CSF samples from one or more centres

were pooled in several studies opening a potential for reuse of already analysed samples; this could have resulted in an overestimation of the study population's variability. We did not consider that diagnostic accuracy might depend on sCJD subtype; its distribution might have affected individual study estimates. However, we only included studies that enrolled consecutive patients with suspected sCJD or a representative sample of those with suspected sCJD, so that study populations mirror the patient populations to which diagnostic tests are applied in clinical practice.

## **Conclusion**

Our NMA suggested RT-QuIC as the most powerful biomarker test for the differential diagnosis of sCJD. The indirect comparisons undertaken in the NMA complete the already available head-to-head evidence and confirm that RT-QuIC (potentially in combination with a more easily applicable and screening test like 14-3-3 or t-tau) should be implemented in the composite lifetime reference standard. Our work also pointed out the methodological limitations of previous diagnostic accuracy studies in the field, and the requirements we consider necessary for the design and conduct of future research projects in this setting. New high-quality studies with appropriate study designs are necessary to provide appropriate diagnostic accuracy data for unanswered research questions such as how to improve diagnostic processes in the pre-symptomatic, period and in those with atypical presentations or specific subtypes. These studies represent the evidence needed for future systematic reviews as well as (network) meta-analyses in the differential diagnosis of prion diseases.<sup>48</sup>

## **Article information**

Acknowledgements

We thank all primary study authors who responded to our inquiries.

### Contributors

AK and SP designed the network meta-analysis, wrote the study protocol and conducted the systematic review (screening the literature search, selecting included studies). SP extracted clinical and demographic information, details of the assays and cut-offs used, and contacted study authors for additional information. NR and SP independently extracted the number of true and false positives and negatives. SP, AK, and NR did an independent risk of bias assessment for all included studies. NR did the statistical analysis. NR, AK and SP analysed and interpreted the data, and wrote the report's draft with input from SK, AZ and GR. All authors critically reviewed the report and approved the final submitted manuscript version. NR and SP contributed equally as first authors. Both had full access to all of the data in the study and take responsibility for the integrity of the data and the data analysis accuracy.

### Funding

This study was supported by intramural funds from the Institute of Epidemiology and Social Medicine, University of Münster, Germany.

### Competing interests

None declared.

### References

1. Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. *Brain*. Narnia; 2007;130:1350–1359.

2. Zerr I, Parchi P. Sporadic Creutzfeldt–Jakob disease. *Handb Clin Neurol*. 2018. p. 155–174.
3. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Brain*. 2009;132:2659–2668.
4. Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. *F1000Research*. 2017;6:2053.
5. National CJD Research & Surveillance Unit (NCJDRSU). Diagnostic criteria for human prion disease [online]. 2017. Accessed at: [https://www.cjd.ed.ac.uk/sites/default/files/criteria\\_0.pdf](https://www.cjd.ed.ac.uk/sites/default/files/criteria_0.pdf). Accessed January 7, 2021.
6. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic creutzfeldt-jakob disease report of the guideline development subcommittee of the American academy of neurology. *Neurology*. 2012;79:1499–1506.
7. Behaeghe O, Mangelschots E, De Vil B, Cras P. A systematic review comparing the diagnostic value of 14-3-3 protein in the cerebrospinal fluid, RT-QuIC and RT-QuIC on nasal brushing in sporadic Creutzfeldt–Jakob disease. *Acta Neurol Belg*. Springer International Publishing; 2018;118:395–403.
8. Karch A, Koch A, Zapf A, Zerr I, Karch A. Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard. *J Clin Epidemiol*. United States; 2016;78:73–82.
9. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology*. 2002;58:192–197.
10. Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155:529–536.

11. Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. *Neurology*. 2012;79:547–552.
12. R Core Team. R: a language and environment for statistical computing [online]. R Found. Stat. Comput. Vienna, Austria Vienna, Austria; 2019. Accessed at: <https://www.r-project.org/>.
13. Zapf A, Castell S, Morawietz L, Karch A. Measuring inter-rater reliability for nominal data - Which coefficients and confidence intervals are appropriate? *BMC Med Res Methodol*. England: BioMed Central; 2016;16:93.
14. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*. 2005;58:882–893.
15. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. *J Clin Epidemiol*. 2006;59:1331–1332.
16. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw*. 2015;67.
17. Vogelgesang F, Schlattmann P, Dewey M. The evaluation of bivariate mixed models in meta-analyses of diagnostic accuracy studies with SAS, stata and R. *Methods Inf Med*. 2018;57:111–119.
18. Nyaga VN, Arbyn M, Aerts M. Beta-binomial analysis of variance model for network meta-analysis of diagnostic test accuracy data. *Stat Methods Med Res*. 2018;27:2554–2566.
19. Carpenter B, Gelman A, Hoffman MD, et al. Stan: A Probabilistic Programming Language. *J Stat Softw*. 2017;76.
20. Stan Development Team. RStan: the R interface to Stan [online]. 2019. Accessed at:

<http://mc-stan.org/>.

21. Rudge P, Hyare H, Green A, Collinge J, Mead S. Imaging and CSF analyses effectively distinguish CJD from its mimics. *J Neurol Neurosurg Psychiatry*. 2018;89:461–466.
22. Wang LH, Bucelli RC, Patrick E, et al. Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. *J Neurol*. 2013;260:498–506.
23. Abu-Rumeileh S, Baiardi S, Polischi B, et al. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QuIC. *J Neurol*. Springer Berlin Heidelberg; 2019;266:3136–3143.
24. Baldeiras IE, Ribeiro MH, Pacheco P, et al. Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. *J Neurol*. D. Steinkopff-Verlag; 2009;256:1540–1550.
25. Bizzi A, Pascuzzo R, Blevins J, et al. Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging. *JAMA Neurol*. 2020;77:1141.
26. Bongiani M, Orrù C, Groveman BR, et al. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. *JAMA Neurol*. American Medical Association; 2017;74:155.
27. Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. *J Neurol Neurosurg Psychiatry*. BMJ Publishing Group Ltd; 2010;81:1243–1248.
28. Cuadrado-Corrales N, Jiménez-Huete A, Albo C, et al. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. *BMC Neurol*. BioMed Central; 2006;6:25.
29. Fiorini M, Iselle G, Perra D, et al. High diagnostic accuracy of RT-QuIC assay in a

- prospective study of patients with suspected sCJD. *Int J Mol Sci.* 2020;21:1–10.
30. Franceschini A, Baiardi S, Hughson AG, et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. *Sci Rep.* Nature Publishing Group; 2017;7:10655.
  31. Lattanzio F, Abu-Rumeileh S, Franceschini A, et al. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A $\beta$ 42 levels. *Acta Neuropathol.* Springer Berlin Heidelberg; 2017;133:559–578.
  32. Leitão MJ, Baldeiras I, Almeida MR, et al. Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3 $\gamma$  assay. *Neuroscience.* Pergamon; 2016;322:398–407.
  33. Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. *Neurology.* 2020;95:e1017–e1026.
  34. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology.* Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2006;67:637–643.
  35. Simon SLR, Peterson A, Phillipson C, et al. Prospective Study Demonstrates Utility of EP-QuIC in Creutzfeldt–Jakob Disease Diagnoses. *Can J Neurol Sci / J Can des Sci Neurol.* Epub 2020 Jul 10.:1–3.
  36. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry.* BMJ Publishing Group Ltd; 2003;74:1210–1214.
  37. Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. *Ann Neurol.* John Wiley & Sons, Ltd;

- 1998;43:32–40.
38. Holtman GA, Berger MY, Burger H, et al. Development of practical recommendations for diagnostic accuracy studies in low-prevalence situations. *J Clin Epidemiol*. Elsevier Inc; 2019;114:38–48.
  39. European Medicines Agency. Clinical evaluation of diagnostic agents. Doc. Ref. CPMP/EWP/1119/98/Rev. 2010.
  40. U.S. Food & Drug Administration. Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff. FDA-2020-D-0957 2007.
  41. Reitsma JB, Rutjes AWS, Whiting P, Vlassov V V., Leeflang MMG, Deeks JJ. Chapter 9: Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. *Cochrane Handb Syst Rev Diagnostic Test Accuracy Version 100*. The Cochrane Collaboration; 2009.
  42. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*. Epub 2015 Oct 28.:h5527.
  43. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. *Acta Neuropathol*. 2020;140:267–278.
  44. Zerr I, Budka H, Kallenberg K, Steinhoff BJ, Weber JR, Sturzenegger M. Creutzfeldt-Jakob-Krankheit, S1-Leitlinie. In: Deutsche Gesellschaft für Neurologie, editor. *Leitlinien für Diagnostik und Ther der Neurol*. 2018.
  45. Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. *Neurology*. 2018;91:e331–e338.
  46. Gerke O, Høilund-Carlsen PF, Vach W. Analyzing paired diagnostic studies by estimating

the expected benefit. *Biometrical J.* 2015;57:395–409.

47. Lewczuk P, Riederer P, O’Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World J Biol Psychiatry.* 2018;19:244–328.
48. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. *Ann Intern Med.* 2015;162:777.

**Table 1:** Results of diagnostic sCJD blood or CSF biomarker studies that met the inclusion criteria

		All		Definite		Probable		Possible		Non-CJD cases	
		sCJD cases									
Study	Biomarker	TP	FN	TP	FN	TP	FN	TP	FN	TN	FP
Abu-Rumeileh et al. 2019	14-3-3 $\beta$	64	16	64	16					72	37
	14-3-3 $\gamma$	70	10	70	10					75	34
	NfL	79	1	79	1					47	62
	RT-QuIC	60	2	60	2					53	0
	t-tau	74	6	74	6					86	23
Baldeiras et al. 2009	14-3-3 $\beta$	29	1	29	1					32	9
	p-tau181/t-tau	28	2	28	2					39	2
	S100B	28	2	28	2					38	3
	t-tau	27	3	27	3					39	2
	t-tau/A $\beta$ 42	28	2	28	2					39	2
Bizzi et al. 2020	14-3-3 $\beta$	295	26	295	26					9	30
	RT-QuIC	68	11	68	11					9	0
	t-tau	340	51	340	51					37	24
Bongianni et al. 2017	14-3-3 $\beta$	49	9	26	2	23	7			10	7
	RT-QuIC	excluded (samples selected based on negative PQ-CSF findings)									
	t-tau	42	10	23	7	19	3			3	6
Chohan et al. 2010	14-3-3 $\beta$	210	35	210	35					127	44
	S100B	158	85	158	85					152	17
	t-tau	175	41	175	41					115	20
Cuadrado-Corrales et al. 2006	14-3-3 $\beta$	155	22	67	8	88	14			480	15
Fiorini et al. 2020	14-3-3 $\beta$	87	15	54	7	33	8			37	43
	RT-QuIC	98	4	58	3	40	1			80	0
	t-tau	87	15	56	5	31	10			56	24
Franceschini et al. 2017	14-3-3 $\beta$	110	14	56	7	54	7			24	18
	RT-QuIC	120	4	61	2	59	2			42	0
	t-tau	117	7	58	5	59	2			26	16
Lattanzio et al. 2017	14-3-3 $\beta$	259	53	155	31	80	17	24	5	133	79
	RT-QuIC	excluded (PQ-CSF assay)									
	t-tau	278	34	164	22	90	7	24	5	158	54
Leitão et al. 2016	14-3-3 $\beta$	72	0	72	0					46	27
	14-3-3 $\gamma$	69	3	69	3					69	4
	p-tau181/t-tau	69	3	69	3					64	9
	t-tau	excluded (cut-off value not within $\pm 10\%$ of 1300 pg/mL)									
Otto et al. 2002	14-3-3 $\beta$	94	15	94	15					70	15
	t-tau	103	6	103	6					75	10
Rhoads et al. 2020	14-3-3 $\beta$	excluded (not only sCJD cases)									
	RT-QuIC	408	31	408	31					69	1
	t-tau	excluded (not only sCJD cases)									

		All		Definite	Probable	Possible	Non-CJD cases				
		sCJD cases									
Study	Biomarker	TP	FN	TP	FN	TP	FN	TP	FN	TN	FP
Sanchez-Juan et al. 2006	14-3-3 $\beta$	excluded (high risk of incorporation bias)									
	NSE	379	138	level of certainty of sCJD diagnosis not reported						12	0
	S100B	483	106							7	3
	t-tau	704	115							13	1
Simon et al. 2020	14-3-3 $\gamma$	103	19							452	49
	RT-QuIC	117	5							496	5
	t-tau	112	10							442	59
Van Everbroeck et al. 2003	14-3-3 $\beta$	52	0	47	0	5	0			183	15
	t-tau	45	7							193	5
Zerr et al. 1998	14-3-3 $\beta$	155	19	62	3	64	5	29	11	155	9

FN: false negative test results; FP: false positive test results; TN: true negative test results; TP: true positive test results

**Table 2:** Results of network meta-analyses (sorted by accuracy)

Biomarker	Definite, probable, or possible sCJD			Definite or probable sCJD			Definite sCJD		
	Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy
RT-QuIC	0.93 (0.87, 0.96)	0.96 (0.87, 0.99)	0.94	0.93 (0.86, 0.96)	0.96 (0.87, 0.99)	0.94	0.91 (0.83, 0.96)	0.96 (0.85, 1.00)	0.93
p-tau181/ t-tau	0.91 (0.79, 0.98)	0.84 (0.58, 0.96)	0.88	0.91 (0.76, 0.98)	0.84 (0.59, 0.96)	0.88	0.90 (0.73, 0.98)	0.83 (0.58, 0.96)	0.88
t-tau/ A $\beta$ 42	0.86 (0.64, 0.97)	0.82 (0.47, 0.98)	0.84	0.87 (0.63, 0.98)	0.83 (0.48, 0.97)	0.85	0.86 (0.60, 0.98)	0.82 (0.46, 0.97)	0.84
14-3-3 $\gamma$	0.87 (0.76, 0.95)	0.80 (0.58, 0.92)	0.83	0.86 (0.74, 0.94)	0.79 (0.59, 0.93)	0.83	0.88 (0.72, 0.96)	0.75 (0.47, 0.92)	0.82
t-tau	0.88 (0.84, 0.91)	0.77 (0.66, 0.86)	0.82	0.88 (0.84, 0.91)	0.76 (0.63, 0.85)	0.82	0.87 (0.81, 0.92)	0.72 (0.58, 0.82)	0.80
14-3-3 $\beta$	0.88 (0.84, 0.92)	0.69 (0.58, 0.79)	0.79	0.89 (0.83, 0.92)	0.69 (0.57, 0.79)	0.79	0.89 (0.84, 0.93)	0.69 (0.57, 0.79)	0.79
S100B	0.77 (0.64, 0.89)	0.81 (0.58, 0.94)	0.79	0.75 (0.55, 0.90)	0.85 (0.63, 0.95)	0.80	0.74 (0.53, 0.91)	0.84 (0.59, 0.95)	0.79
NSE	0.71 (0.50, 0.88)	0.85 (0.52, 0.99)	0.78						
NfL	0.94 (0.80, 0.99)	0.46 (0.17, 0.80)	0.70	0.93 (0.74, 0.99)	0.46 (0.15, 0.80)	0.70	0.92 (0.72, 0.99)	0.45 (0.15, 0.79)	0.69

## Figures

Figure 1: Flow chart of study selection

Figure 2: Sensitivity and specificity of CSF biomarkers for the diagnosis of definite sCJD


*CI: Confidence interval; FPR: False positive rate; SD: Standard deviation; TPR: True positive rate*




Figure 3: Network plot

*The thickness of the nodes is proportional to the number of direct comparisons.*






Figure 4: Results of network meta-analyses (stratified by level of certainty of sCJD diagnosis)


*CI: Confidence interval*



**14-3-3β****14-3-3γ****NfL**

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.25.21254312>; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**p-tau181/t-tau****RT-QuIC****S100B****t-tau****t-tau/Aβ-42**




▲ Definite sCJD

● Definite or probable sCJD

■ Definite, probable or possible sCJD

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.25.21241411>; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Posterior mean (95% equal-tailed CI)



Posterior mean (95% equal-tailed CI)